MHY1485

Research use only, not for human use.

MHY1485 is a mTOR activator; inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes.

MHY1485 is a mTOR activator; inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes.(In Vitro):MHY1485 (10 μM; 4 hours) shows that GCDC-induced autophagic activity is inhibited by upregulating p-mTOR expression and downregulating LC3 and p62 expression in HCC cells.MHY1485 (5 μM; 6 hours) increases the LC3II/LC3I ratio in a dose and time-dependently manner due to presumably inhibited LC3II degradation in rat liver Ac2F cells.MHY1485 (0.5-2 μM; 6 hours) increases the phosphorylation of mTOR at ser2448 and upregulates the level of phosphorylation of 4E-BP1 in a dose-dependently manner in Ac2F cells.(In Vivo):MHY1485 (intraperitoneal injection; 10 mg/kg, 2 days) blocks the autophagy signaling induced by follicle-stimulating hormone (FSH). It increases p-mTOR and p-S6K1 expression levels, whereas LC3 expression shows no marked change compared to that in the control group.

MHY1485 (10 μM; 4 hours) shows that GCDC-induced autophagic activity is inhibited by upregulating p-mTOR expression and downregulating LC3 and p62 expression in HCC cells.MHY1485 (5 μM; 6 hours) increases the LC3II/LC3I ratio in a dose and time-dependently manner due to presumably inhibited LC3II degradation in rat liver Ac2F cells.MHY1485 (0.5-2 μM; 6 hours) increases the phosphorylation of mTOR at ser2448 and upregulates the level of phosphorylation of 4E-BP1 in a dose-dependently manner inAc2F cells. Western Blot Analysis Cell Line:HCC cells Concentration:10 μM Incubation Time:4 hours Result:Upregulated p-mTOR and downregulated LC3 and p62 expression.

MHY1485 (intraperitoneal injection; 10?mg/kg, 2 days) blocks the autophagy signaling induced by follicle-stimulating hormone (FSH).It increases p-mTOR and p-S6K1 expression levels,whereas LC3 expression shows no marked change compared to that in the control group. Animal Model:4-week-old female ICR mice Dosage:10?mg/kg, 2 days Administration:Intraperitoneal injection Result:Suppressed the autophagy level following FSH treatment.?

MHY-1485 | MHY1485 | MHY 1485

PI3K/Akt/mTOR signaling

mTOR

mTOR

Cancer

——

326914-06-1

387.39

C17H21N7O4

>98% (HPLC)

DMSO: 33 mg/mL (85.18 mM)

O=[N+](C1=CC=C(NC2=NC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=C1)[O-]

4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine

(-20℃)

With Ice Pack

≥ 2 years